ACAD
34.45
-0.48
-1.37%
AEMD
3.75
+0.1
+2.74%
APRI
2.29
+0.03
+1.33%
ARNA
1.45
+0.02
+1.40%
ATEC
2.07
-0.61
-22.76%
CNAT
4.59
+0.19
+4.32%
CRXM
0.2
-0.01
-4.76%
CYTX
1.64
+0.03
+1.86%
DXCM
76.08
-0.82
-1.07%
GNMK
13.14
+0.12
+0.92%
HALO
13.46
-0.03
-0.22%
ILMN
167.69
-0.1
-0.06%
INNV
0.11
0.00
+1.63%
INO
5.95
+0.03
+0.51%
ISCO
1.65
-0.1
-5.71%
ISIS
57.56
0.00
0.00%
LGND
103.79
-0.28
-0.27%
LPTN
2.93
0.00
0.00%
MBVX
2.51
+0.06
+2.45%
MEIP
1.57
+0.03
+1.95%
MNOV
5.81
+0.01
+0.17%
MRTX
5.1
-0.05
-0.97%
MSTX
0.107
+0.01
+9.744%
NBIX
41.5
-0.22
-0.53%
NUVA
74.295
-0.255
-0.342%
ONCS
1.25
-0.01
-0.79%
ONVO
3.01
0.00
0.00%
OREX
4
0.00
0.00%
OTIC
13.1
-0.05
-0.38%
QDEL
21.675
+0.365
+1.713%
RCPT
231.96
0.00
0.00%
RGLS
1.25
0.00
0.00%
RMD
71.31
+0.02
+0.03%
SPHS
2.58
+0.03
+1.18%
SRNE
4.2
+0.05
+1.20%
TROV
1.15
+0.15
+15.00%
VICL
2.13
-0.05
-2.29%
VOLC
18
0.00
0.00%
ZGNX
10.4
+0.05
+0.48%
ACAD
34.45
-0.48
-1.37%
AEMD
3.75
+0.1
+2.74%
APRI
2.29
+0.03
+1.33%
ARNA
1.45
+0.02
+1.40%
ATEC
2.07
-0.61
-22.76%
CNAT
4.59
+0.19
+4.32%
CRXM
0.2
-0.01
-4.76%
CYTX
1.64
+0.03
+1.86%
DXCM
76.08
-0.82
-1.07%
GNMK
13.14
+0.12
+0.92%
HALO
13.46
-0.03
-0.22%
ILMN
167.69
-0.1
-0.06%
INNV
0.11
0.00
+1.63%
INO
5.95
+0.03
+0.51%
ISCO
1.65
-0.1
-5.71%
ISIS
57.56
0.00
0.00%
LGND
103.79
-0.28
-0.27%
LPTN
2.93
0.00
0.00%
MBVX
2.51
+0.06
+2.45%
MEIP
1.57
+0.03
+1.95%
MNOV
5.81
+0.01
+0.17%
MRTX
5.1
-0.05
-0.97%
MSTX
0.107
+0.01
+9.744%
NBIX
41.5
-0.22
-0.53%
NUVA
74.295
-0.255
-0.342%
ONCS
1.25
-0.01
-0.79%
ONVO
3.01
0.00
0.00%
OREX
4
0.00
0.00%
OTIC
13.1
-0.05
-0.38%
QDEL
21.675
+0.365
+1.713%
RCPT
231.96
0.00
0.00%
RGLS
1.25
0.00
0.00%
RMD
71.31
+0.02
+0.03%
SPHS
2.58
+0.03
+1.18%
SRNE
4.2
+0.05
+1.20%
TROV
1.15
+0.15
+15.00%
VICL
2.13
-0.05
-2.29%
VOLC
18
0.00
0.00%
ZGNX
10.4
+0.05
+0.48%
Home » Archive by Category

Xconomy

New Data Show Power, Limits of Bluebird’s Gene Therapy For Blood Diseases

November 3, 2016 – 6:00 am

Bluebird Bio is releasing new data this morning that speak to both the potential and the limitations of a gene therapy it’s been developing for two deadly blood diseases, sickle cell disease and…

[[Click headline to continue reading.]]

With Reverse Merger, Miragen to Go Public, Get $40M Boost From Investors

November 1, 2016 – 5:32 am

For privately held biotechs, IPOs are the most common road to the public markets, but they’re not the only way. Reverse merging with a shell company is an alternate path, and that’s how Miragen…

[[Click headline to continue reading.]]

On Front Lines Of Price Dispute, Eye Doctors Wary of New Drug Data

November 1, 2016 – 3:55 am

Drugs that treat a form of vision loss known as age related macular degeneration aren’t just big business. They’re also a controversial part of the national debate over high drug prices, and their…

[[Click headline to continue reading.]]

Bio Roundup: Drug Pricing, Cystic Fibrosis Showdown, Myovant & More

October 28, 2016 – 6:25 am

The 2016 election is (thankfully) almost here, and as one biotech analyst noted this week, a possible Democratic victory is to blame for a big October sell-off in biotech stocks. Since Donald Trump’s…

[[Click headline to continue reading.]]

Despite Low Crop Prices, Corporate and VC Agtech Investments Soar

October 27, 2016 – 4:00 am

Prices for agricultural commodities such as corn, soy, and wheat are at their lowest levels in years, but investment in agricultural technology has never been better. Venture capital firms have…

[[Click headline to continue reading.]]

FDA: Keytruda Now OK For Some Patients With Untreated Lung Cancer

October 24, 2016 – 9:17 pm

The FDA has approved the use of pembrolizumab (Keytruda) for some previously untreated patients with a certain type of lung cancer, the drug’s owner Merck (NYSE: MRK) announced late Monday….

[[Click headline to continue reading.]]

Bio Roundup: Jenkins Gets Mad, Bernie Gets His Pen, CRISPR IPO & J-Lo

October 21, 2016 – 3:30 am

If you’re among those frustrated by the lack of talk about health and science in the three presidential debates, this week perhaps brought you a wee consolation prize. The steady drip of hacked…

[[Click headline to continue reading.]]

BlackThorn Emerges With $40M, New Weapons Against Neuro Disorders

October 20, 2016 – 5:55 am

For three years, a group of investors and experienced neuroscience executives have been stealthily advancing one of the more ambitious new startups in neurology, called BlackThorn Therapeutics. Today…

[[Click headline to continue reading.]]

Arterys, GE Healthcare to Roll Out Next-Gen MRI Scans of Heart

October 19, 2016 – 10:09 am

The healthcare tools of the future often start as research projects in academic medical centers, but they may not break out into widespread clinical practice until some sort of logjam gives way to…

[[Click headline to continue reading.]]

All In One Place: A New Immuno-Oncology Trial Resource

October 19, 2016 – 7:00 am

More than 100 years ago, New York bone surgeon William Coley began to suspect that bacterial infections might be improving the outlook for patients also suffering from cancer. The infections were…

[[Click headline to continue reading.]]